Therefore, we compared the DNA methylation profile in the primary tumor and normal tissue samples of the top four cancers (breast, colorectal, lung and prostate) in order to identify ARF-MDM2-p53 pathway-associated genes, which may be universally hypermethylated in the cancers investigated. The gene discussed is CDKN2A; the disease is cancer.